Exploring Managing Toxicity Of Immunotherapy In Melanoma
Let's dive into the details surrounding Managing Toxicity Of Immunotherapy In Melanoma.
- Michael A. Postow, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, shares advice to community oncologists ...
- Michael A. Postow, MD, and Claire Crowley, RN, discuss the overall
- Dr Au speaks with ecancer at the ACP
- Martin Gore, PhD, FRCP, CBE from the Royal Marsden NHS Foundation, London, UK discusses the risks from
- In our third episode of our special vodcast series, Redefining
In-Depth Information on Managing Toxicity Of Immunotherapy In Melanoma
Omid Hamid, MD, leads the panel discussion on the safety of nivolumab and Dr. Medina is an Assistant Professor of medicine in the Division of Medical Oncology at the University of Colorado Anschutz ... Panelists Robert H.I. Andtbacka, MD, CM; Antoni Ribas, MD, PhD; Michael A. Davies, MD, PhD; Michael A. Postow, MD; and ... Tune in as
Michael A. Postow, MD, and Claire Crowley, RN, discuss the overall
That wraps up our extensive overview of Managing Toxicity Of Immunotherapy In Melanoma.
